Frontline bortezomib, rituximab, cyclophosphamide, ...
In the LYM-3002 study, VR-CAP showed significantly longer median overall survival (90.7 months) compared to R-CHOP (55.7 months) in untreated mantle cell lymphoma patients, with a manageable safety profile. Results support further VR-CAP assessment.
Reference News
Frontline bortezomib, rituximab, cyclophosphamide, ...
In the LYM-3002 study, VR-CAP showed significantly longer median overall survival (90.7 months) compared to R-CHOP (55.7 months) in untreated mantle cell lymphoma patients, with a manageable safety profile. Results support further VR-CAP assessment.